[ASND] Ascendis Pharma A/S

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 19.87 Change: -0.14 (-0.7%)
Ext. hours: Change: 0 (0%)

chart ASND

Refresh chart

Strongest Trends Summary For ASND

ASND is in the long-term up 393% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Fundamental Ratios
Shares Outstanding EPS-2.56 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -64.77% Sales Growth - Q/Q-64.77% P/E-9.38
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-3.8% ROE-4.87% ROI
Current Ratio4.13 Quick Ratio Long Term Debt/Equity Debt Ratio0.28
Gross Margin Operating Margin-46.7% Net Profit Margin-24.89% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities47.91 M Cash From Investing Activities-410 K Cash From Operating Activities-18.4 M Gross Profit
Net Profit-5.04 M Operating Profit-7.06 M Total Assets58.67 M Total Current Assets53.16 M
Total Current Liabilities12.86 M Total Debt Total Liabilities12.86 M Total Revenue2.83 M
Technical Data
High 52 week76.28 Low 52 week38.98 Last close73.46 Last change-1.69%
RSI72.07 Average true range3.59 Beta0.87 Volume16.12 K
Simple moving average 20 days12.77% Simple moving average 50 days15.89% Simple moving average 200 days11.26%
Performance Data
Performance Week5.18% Performance Month12.62% Performance Quart24.3% Performance Half4.2%
Performance Year54.33% Performance Year-to-date17.25% Volatility daily4.01% Volatility weekly8.97%
Volatility monthly18.38% Volatility yearly63.69% Relative Volume225.05% Average Volume141.65 K
New High New Low

News

2019-03-25 14:45:06 | Ascendis Pivotal Growth Hormone Deficiency Study Data Positive

2019-03-25 14:00:00 | Ascendis Pharma Announces Results of Study at ENDO 2019 Evaluating Impact of Hypoparathyroidism on Patient Quality-of-Life

2019-03-24 12:45:00 | Ascendis Pharma Announces Phase 3 heiGHt Trial Demonstrated Superior Efficacy and Comparable Safety and Tolerability of TransCon™ hGH to a Daily Growth Hormone

2019-03-14 13:08:12 | ValueAct Capital’s CBRE Recommendation Delivers 150% Gain

2019-03-12 10:56:02 | What Makes Ascendis Pharma A/S ASND a New Buy Stock

2019-03-07 07:10:00 | Report: Exploring Fundamental Drivers Behind Manulife Financial, Fidelity National Financial, Heritage-Crystal Clean, Ericsson, Ascendis Pharma A/S, and Astec Industries — New Horizons, Emerging Trends, and Upcoming Developments

2019-03-06 14:31:13 | Shareholders Are Raving About How The Ascendis Pharma Share Price Increased 602%

2019-03-06 10:00:00 | Under the Radar Cannabis Stock-THC Therapeutics, Inc.

2019-03-06 04:05:45 | Ascendis Pharma Prices 4.166M ADS Offering @$122/ADS

2019-03-05 20:07:46 | Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

2019-03-05 09:43:02 | Company News For Mar 5, 2019

2019-03-04 16:01:00 | Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

2019-03-04 13:24:20 | Why Ascendis Pharma Is Soaring Today

2019-03-04 06:30:00 | Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone Deficiency

2019-02-28 20:20:45 | Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon CNP as Treatment for Achondroplasia

2019-02-28 07:45:00 | Recent Analysis Shows Intel, Gilead Sciences, Amdocs, Ascendis Pharma A/S, Hill-Rom, and Ingevity Market Influences — Renewed Outlook, Key Drivers of Growth

2019-02-13 09:53:02 | Ascendis Pharma Files IND for Hypoparathyroidism Candidate

2019-02-11 17:27:08 | Ascendis Pharma Initiates Global Phase 2 Trial for TransCon PTH in Adult Subjects with Hypoparathyroidism

2019-01-25 09:18:02 | All You Need to Know About Ascendis Pharma A/S ASND Rating Upgrade to Buy

2019-01-07 09:00:00 | Ascendis Pharma A/S Introduces Vision 3x3: A Strategic Roadmap Through 2025 to Achieve Sustainable Growth Using Multiple Approaches

2018-12-21 16:01:00 | Ascendis Pharma A/S Announces Participation in 37th Annual J.P. Morgan Healthcare Conference

2018-12-12 02:57:10 | Should You Buy Ascendis Pharma A/S ASND?

2018-11-29 02:11:50 | Edited Transcript of ASND earnings conference call or presentation 28-Nov-18 9:30pm GMT

2018-11-28 23:03:09 | Ascendis Pharma A/S ASND Q3 2018 Earnings Conference Call Transcript

2018-11-28 16:05:00 | Ascendis Pharma A/S Reports Third Quarter 2018 Financial Results

2018-11-28 16:01:00 | Ascendis Pharma A/S Announces Positive Preliminary Phase 1 Data for TransCon CNP

2018-11-14 16:15:00 | Ascendis Pharma A/S Announces Third Quarter 2018 Financial Results and Business Update Conference Call on November 28

2018-11-08 16:48:46 | Ascendis Pharma Announces Formation of VISEN Pharmaceuticals to Develop and Commercialize TransCon™ Endocrinology Rare Disease Therapies in China

2018-11-02 09:00:00 | Ascendis Pharma A/S Announces Upcoming Investor Presentations

2018-10-26 08:35:00 | Market Trends Toward New Normal in Ascendis Pharma A/S, Diodes, Laureate Education, Randgold Resources, Fastenal, and LTC Properties — Emerging Consolidated Expectations, Analyst Ratings

2018-10-01 08:00:00 | Today's Research Reports on Trending Tickers: Aurora Cannabis and Ascendis Pharma

2018-09-27 07:55:00 | Factors of Influence in 2018, Key Indicators and Opportunity within Ascendis Pharma A/S, Fluor, InterDigital, Ruth's Hospitality Group, Aramark, and ManTech International — New Research Emphasizes Economic Growth

2018-09-25 10:46:54 | TransCon Tech Is a Major Growth Driver for Ascendis Pharma A/S

2018-09-17 16:10:00 | Ascendis Pharma A/S Announces Support for Children’s Growth Awareness Week and Day 2018

2018-09-06 16:02:00 | Ascendis Pharma A/S Announces Presentations on Technology and Rare Disease Endocrinology Pipeline at September Conferences

2018-08-31 16:01:00 | Ascendis Pharma A/S Announces Upcoming Investor Presentations

2018-08-31 11:48:04 | Ascendis Pharma ASND Q2 2018 Earnings Conference Call Transcript

2018-08-29 22:01:38 | Edited Transcript of ASND earnings conference call or presentation 29-Aug-18 8:30pm GMT

2018-08-29 16:01:00 | Ascendis Pharma A/S Reports Second Quarter 2018 Financial Results

2018-08-29 14:30:00 | Ascendis Pharma A/S Sponsored ADR to Host Earnings Call

2018-08-15 16:15:00 | Ascendis Pharma A/S Announces Second Quarter 2018 Financial Results and Business Update Conference Call on August 29

2018-08-02 07:00:00 | Ascendis Pharma A/S Announces Participation in the 2018 Wedbush PacGrow Healthcare Conference

2018-07-23 16:44:56 | Ascendis Pharma A/S Announces Poster Presentation on TransCon Technology at the Controlled Release Society Annual Meeting

2018-06-06 17:35:31 | Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon PTH as Treatment for Hypoparathyroidism

2018-06-06 08:15:00 | Investor Expectations to Drive Momentum within Gladstone Commercial, Old Line Bancshares, Randgold Resources, Turning Point Brands, Capella Education, and Ascendis Pharma A/S — Discovering Underlying Factors of Influence

2018-05-30 21:53:48 | Edited Transcript of ASND earnings conference call or presentation 30-May-18 8:30pm GMT

2018-05-30 16:02:00 | Ascendis Pharma A/S Reports First Quarter 2018 Financial Results

2018-05-16 16:20:00 | Ascendis Pharma A/S Announces First Quarter 2018 Financial Results and Business Update Conference Call on May 30

2018-05-10 07:25:00 | Wired News - Ascendis Pharma Dosed First Subjects in First-in-Human Phase-1 Trial of TransCon CNP

2018-05-08 07:00:00 | Ascendis Pharma A/S Announces Dosing of First Subjects in Phase 1 Trial of TransCon CNP